GlassScriptPhysician profile
Estelle Kazar
NPI 1356015713
$1,297.99
in general payments reported to CMS, 2019-2025
11 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.15 · 2022: $61.67 · 2023: $23.29 · 2024: $145 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $528.21 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Shockwave Medical, INC | $392.66 | 2025 | |
| Medtronic, INC. | $128.37 | 2021-2025 | Venaseal |
| Cordis US Corp. | $57.57 | 2025 | Mynx Control Venous |
| E.R. Squibb & Sons, L.L.C. | $34.68 | 2024 | Eliquis |
| Imperative Care, INC | $31.19 | 2025 | Symphony Catheter |
| Atricure, INC. | $28.95 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Cardiva Medical, INC. | $26.55 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Pharmaceuticals, INC | $24.55 | 2024 | Xarelto |
| Getinge USA Sales, LLC | $23.29 | 2023 | Cardiosave Hybrid, Type B Plug |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Estelle Kazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.